Lars Lööf
About
In The Last Decade
Lars Lööf
129 papers receiving 6.2k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Surgery 2.7k
- Hepatology 2.6k
- Epidemiology 2.5k
- Pulmonary and Respiratory Medicine 1.3k
- Genetics 1.0k
Countries citing papers authored by Lars Lööf
This map shows the geographic impact of Lars Lööf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Lööf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Lööf more than expected).
Fields of papers citing papers by Lars Lööf
This network shows the impact of papers produced by Lars Lööf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Lööf. The network helps show where Lars Lööf may publish in the future.
Co-authorship network of co-authors of Lars Lööf
This figure shows the co-authorship network connecting the top 25 collaborators of Lars Lööf. A scholar is included among the top collaborators of Lars Lööf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Lööf. Lars Lööf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [The willingness to pay for new drugs is based on ethical principles]. | 1 |
| 2 | 117 | |
| 3 | 17 | |
| 4 | [Clinical research and continuing education on county hospital level. Experiences with cooperation between health care and academies]. | 1 |
| 5 | 7 | |
| 6 | 63 | |
| 7 | 23 | |
| 8 | 53 | |
| 9 | Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. breakdown → | 578 |
| 10 | CA 19-9, CA50 and CA242 as tools for diagnosis of cholangiocarcinoma (CC) in patients with primary sclerosing cholangitis (PSC). | 4 |
| 11 | Glutathione levels and lipidperoxidation in patients with alcoholic hepatitis. | 5 |
| 12 | 65 | |
| 13 | 4 | |
| 14 | 52 | |
| 15 | 7 | |
| 16 | 12 | |
| 17 | 12 | |
| 18 | The clinical diagnosis of 'gastritis'. Aspects of demographic epidemiology and health care consumption based on a nationwide sample survey. | 39 |
| 19 | 13 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.